Unfortunately, some ER+ BCa tumours in advanced ER+ BCa patients acquire resistance to tamoxifen [2], and due to the real or perceived side effects of this treatment, uptake and adherence rates of tamoxifen regimens in the preventative setting are poor [3,4,5,6]. This evidence concerns the gene ESR1 and neoplasm.